A Phase I Study of BTRC4017A in Participants With Locally Advanced or Metastatic HER2-Expressing Cancers

Official Title

A Phase I, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of BTRC4017A Administered Intravenously in Patients With Locally Advanced or Metastatic HER2-Expressing Cancers

Summary:

This study will evaluate the safety, tolerability, and pharmacokinetics of BTRC4017A in participants with locally advanced or metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-expressing cancers.

Trial Description

Primary Outcome:

  • Percentage of Participants with Adverse Events
Secondary Outcome:
  • Serum Concentration of BTRC4017A
  • Area Under the Serum Concentration vs. Time Curve (AUC) of BTRC4017A
  • Maximum Observed Serum Concentration (Cmax) of BTRC4017A
  • Minimum Observed Serum Concentration (Cmin) of BTRC4017A
  • Clearance (CL) of BTRC4017A
  • Volume of Distribution at Steady State (Vss) of BTRC4017A
  • Objective Response (OR) as Determined by the Investigator According to Response Evaluation Criteria In Solid Tumours v1.1 (RECIST v1.1)
  • Duration of Response (DOR)
  • Anti-Drug Antibody (ADA) Levels of BTRC4017A

View this trial on ClinicalTrials.gov

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.

Resources

Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society